Loading...
•
Sep 30, 2024
Verona Pharma Q3 2024 Earnings Report
Verona Pharma reported Q3 2024 financial results, highlighting the launch of Ohtuvayre and ongoing clinical trials.
Key Takeaways
Verona Pharma reported Q3 net sales of $5.6 million for Ohtuvayre. The company initiated two Phase 2 clinical trials and cash and cash equivalents were $336.0 million as of September 30, 2024.
Ohtuvayre launch recorded Q3 net sales of $5.6 million.
October net sales exceeded Q3 sales.
Over 2,200 unique prescribers and 5,000 prescriptions filled across a broad COPD population.
Two Phase 2 programs were initiated.
Forward Guidance
Verona Pharma believes cash and cash equivalents will enable them to fund planned operating expenses and capital expenditure requirements through at least the end of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...